Name
sMD-2 and sMD-2/TLR4, Human, mAb 4H1
Catalog nr
HM2243 (lot number and expiry date are indicated on the label)
Short description
The monoclonal antibody 4H1 reacts with soluble MD-2 (sMD-2) and the sMD-2/Toll-like receptor 4 (TLR4, CD284) complex. TLRs belong to a family of proteins that specifically recognizes and senses microbial products. They are highly conserved throughout evolution and act as innate immune recognition receptors against many pathogens. TLR4 is a functional receptor for gram-negative bacterial lipo...
Size
100 µg
Application
FS , IA , IF , W
Technical datasheet
Description
The monoclonal antibody 4H1 reacts with soluble MD-2 (sMD-2) and the sMD-2/Toll-like receptor 4 (TLR4, CD284) complex. TLRs belong to a family of proteins that specifically recognizes and senses microbial products. They are highly conserved throughout evolution and act as innate immune recognition receptors against many pathogens. TLR4 is a functional receptor for gram-negative bacterial lipopolysaccharides (LPS). TLR4 associates with MD-2 which is absolutely required for LPS-induced activation of TLR4.

MD-2 exists as a cell surface protein in association with TLR4. It also exists as secreted forms consisting of MD-2 monomer and multimers. Circulating sMD-2 is mainly present as a doublet of ~20 and 25 kD, representing differentially glycosylated forms. Unlike TLR4, sMD-2 binds directly LPS without the need of soluble CD14 (sCD14). However, LPS-MD-2 interactions are increased when LPS is pretreated with CD14. Only monomeric sMD-2 is biologically active and able to associate with TLR4 and LPS. sMD-2 circulates in plasma of healthy individuals as a non-active, polymeric protein. In septic plasma, the total amount of sMD-2 was strongly elevated and contained both sMD-2 polymers and monomers. Soluble MD-2 is proposed to be an important mediator of organ inflammation during sepsis. During experimental human endotoxemia, the monomeric and total sMD-2 content in plasma increased with the kinetics of an acute phase protein. This parallels enhanced TLR4 costimulatory activity. In vitro studies revealed that sMD-2 release appears to be restricted to endothelial and dendritic cells.

The monoclonal antibody 4H1 reacts with both the monomeric and the polymeric form of sMD-2. In addition, the monoclonal antibody 4H1 is able to inhibit LPS binding to MD-2.It does not cross-react with mouse MD-2.
Cross Reactivity
 Cross reactant  Reactivity
 Human  Yes
Immunogen
Baculovirally expressed His-tagged human MD-2
Formulation
1 ml (100 µg/ml) 0.2 µm filtered antibody solution in PBS, containing 0.1% bovine serum albumin.
Species
Mouse IgG1
Application
The monoclonal antibody 4H1 can be used for immuno assay, Western blotting and immunofluorescence. Furthermore, the antibody can be used to inhibit LPS binding to MD-2 in vitro.
Use
For immuno assay, Western blotting and immunofluorescence, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, dilutions have to be made according to the amounts of MD-2 to be inactivated.
Aliases
Lymphocyte antigen 96, ESOP-1, LY96
Storage and stability
Product should be stored at 4°C. Under recommended storage conditions, product is stable for one year.
References
  1. Viriyakosol, S et al; Characterization of monoclonal antibodies to human soluble MD-2 protein. Hybridoma 2006, 25: 349
Precautions
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use or derivation of this product.
Also available
References
  1. Viriyakosol, S et al; Characterization of monoclonal antibodies to human soluble MD-2 protein. Hybridoma 2006, 25: 349
Scientific info
Useful new antibodies for studies of MD-2 expression and function in health and disease

Hycult Biotech introduces four monoclonal antibodies to study both soluble and membrane bound human MD-2. MD-2 is a 20-25 kD glycoprotein that associates with the extracellular portion of Toll-like receptor 4 (TLR4, CD284).  TLR4 association with MD-2 is absolutely required for LPS-induced activation of TLR4.

MD-2 also exists in secreted forms consisting of MD-2 monomers and multimers. Only monomeric soluble MD-2 (sMD-2) is biologically active and able to associate with TLR4 and LPS. sMD-2 circulates in plasma of healthy individuals as non-active, polymeric protein. In septic plasma, the total amount of sMD-2 was strongly elevated and contained both sMD-2 monomers and polymers.

sMD-2 is proposed to be an important mediator of organ inflammation during sepsis. During experimental human endotoxemia, the monomeric and total sMD-2 content in plasma increased with the kinetics of an acute phase protein. This parallels enhanced TLR4 costimulatory activity. In vitro studies revealed that sMD-2 release appears to be restricted to endothelial and dendritic cells.
 
The four antibodies Hycult Biotech introduces here are reactive with MD-2 in its various forms. Three of them are useful for studies on biological activity of MD-2. All four monoclonal antibodies are available as biotinylated and FITC-labeled conjugates.

Cat. No.

Product

MD-2

sMD-2

MD-2/TLR4 complex

Inhibition of biological activity

Other applications

HM2243

sMD-2 and sMD-2/TLR4, human, mAb 4H1

+

+

+

+

IA IF W

HM2244

sMD-2, human, mAb 10D5

-

+

-

-

IA IF W

HM2245

MD-2, human, mAb 18H10

+

-

+

+

FC

HM2246

TLR4/MD-2, human, mAb 7E3

-

-

+

+

FC


References:
1. Viriyakosol, S et al; Characterization of monoclonal antibodies to human soluble MD-2 protein. Hybridoma 2006, 25: 349
2. Pugin, J et al; Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock. Blood 2004, 104: 4071
3. Daubeuf, B et al; TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J Immunol 2007, 179: 6107
4. Elson, G et al; Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria. Blood 2007, 109: 1574
5. Tissieres, P et al; Soluble MD-2 is an acute-phase protein and an opsonin for Gram-negative bacteria. Blood 2008, 111: 2122